A composition including, (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid, is provided. Moreover, a kit which includes: a syringe, a mineral particle covered with endothelial cells and mesenchymal cells organized in 2 or more cell layers attached to the mineral particle, and hyaluronic acid, is also provided. Last, a method for filling a gap in a bone of a subject in need thereof, including contacting the gap with a composition of: (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid is provided.

A method of treating a bacterial infection in a subject includes administering at least a first finely divided (particulate) material, which may have at least a second material, the first material is not bioresorbable or very slowly bioresorable and the second material or materials are bioresorbable at a higher rate than the first material, allowing a certain period of time to pass in order to provide for the first particulate material to be exposed to the body and/or second material or materials to be wholly or partly absorbed by the body of the subject, and administering one or more pharmaceutically active compounds. The first material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds, and the second material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds. The pharmaceutically active compound is a compound capable of treating or ameliorating a bacterial infection.

A method of treating a bacterial infection in a subject includes administering at least a first finely divided (particulate) material, which may have at least a second material, the first material is not bioresorbable or very slowly bioresorable and the second material or materials are bioresorbable at a higher rate than the first material, allowing a certain period of time to pass in order to provide for the first particulate material to be exposed to the body and/or second material or materials to be wholly or partly absorbed by the body of the subject, and administering one or more pharmaceutically active compounds. The first material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds, and the second material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds. The pharmaceutically active compound is a compound capable of treating or ameliorating a bacterial infection.

A method of treating a bacterial infection in a subject includes administering at least a first finely divided (particulate) material, which may have at least a second material, the first material is not bioresorbable or very slowly bioresorable and the second material or materials are bioresorbable at a higher rate than the first material, allowing a certain period of time to pass in order to provide for the first particulate material to be exposed to the body and/or second material or materials to be wholly or partly absorbed by the body of the subject, and administering one or more pharmaceutically active compounds. The first material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds, and the second material is optionally pre-loaded or soaked with one or more pharmaceutically active compounds. The pharmaceutically active compound is a compound capable of treating or ameliorating a bacterial infection.

A bone cement composition including a powder component, a liquid component, and hyaluronic acid (HA) or a salt thereof in an amount ranging from 0.01% to 10% w/w in the powder component and/or in the liquid component. The powder component includes calcium phosphate compounds having at least alpha-tricalcium phosphate (α-TCP) and having at least calcium-deficient apatite (CDA). Also, a bone cement obtainable by a process including the following steps: (i) the preparation of a cement composition by mixing the powder component, and the liquid component and (ii) the setting of the cement composition. Further, the use in vitro or ex vivo of a bone cement composition or bone cement in the manufacture of a dental or bony implant.

A bone cement composition including a powder component, a liquid component, and hyaluronic acid (HA) or a salt thereof in an amount ranging from 0.01% to 10% w/w in the powder component and/or in the liquid component. The powder component includes calcium phosphate compounds having at least alpha-tricalcium phosphate (α-TCP) and having at least calcium-deficient apatite (CDA). Also, a bone cement obtainable by a process including the following steps: (i) the preparation of a cement composition by mixing the powder component, and the liquid component and (ii) the setting of the cement composition. Further, the use in vitro or ex vivo of a bone cement composition or bone cement in the manufacture of a dental or bony implant.

A bone cement composition including a powder component, a liquid component, and hyaluronic acid (HA) or a salt thereof in an amount ranging from 0.01% to 10% w/w in the powder component and/or in the liquid component. The powder component includes calcium phosphate compounds having at least alpha-tricalcium phosphate (α-TCP) and having at least calcium-deficient apatite (CDA). Also, a bone cement obtainable by a process including the following steps: (i) the preparation of a cement composition by mixing the powder component, and the liquid component and (ii) the setting of the cement composition. Further, the use in vitro or ex vivo of a bone cement composition or bone cement in the manufacture of a dental or bony implant.

A material for a bone implant includes a surface which contains a metal-based material, a metal alloy, an oxide ceramics material, a polymer material, a composite material or combinations thereof. An organic polymer matrix is covalently bonded to the surface. A substance is linked with the organic polymer matrix for binding embedded metal ions or nanoparticles. A calcium phosphate is embedded in the organic polymer matrix. As a result, the material for the bone implant is biocompatible and corrosion can be slowed down or even prevented.

A material for a bone implant includes a surface which contains a metal-based material, a metal alloy, an oxide ceramics material, a polymer material, a composite material or combinations thereof. An organic polymer matrix is covalently bonded to the surface. A substance is linked with the organic polymer matrix for binding embedded metal ions or nanoparticles. A calcium phosphate is embedded in the organic polymer matrix. As a result, the material for the bone implant is biocompatible and corrosion can be slowed down or even prevented.

Implantable bone compositions are provided. The implantable compositions comprise hydratable bone putties. The hydratable bone putties comprise porous ceramic granules having an average diameter from about 50 μm to 800 μm. The porous ceramic granules comprise hydroxyapatite and beta-tricalcium phosphate. The implantable bone compositions further include collagen carriers. In some embodiments, the hydratable bone putty can be hydrated to form a non-settable flowable cohesive cement or gel. Methods of making and using the implantable compositions are also provided.